Skye Bioscience Faces Class Action Over Misleading Claims About Nimacimab Drug Efficacy

Skye Bioscience Faces Class Action Over Misleading Drug Claims

Skye Bioscience, Inc. is embroiled in a class action lawsuit filed by national plaintiffs' law firm Berger Montague PC, alleging that the company misled investors about the efficacy of its lead drug candidate, nimacimab. The lawsuit targets investors who acquired Skye securities between November 4, 2024, and October 3, 2025, claiming that the company made false statements regarding nimacimab's potential. This legal development is particularly significant for Skye, which is a clinical-stage biotechnology firm based in San Diego focused on treatments for obesity and metabolic diseases. The allegations come in the wake of disappointing results from the Phase 2a CBeyond trial of nimacimab, which failed to achieve its primary weight-loss endpoint compared to a placebo.

The lawsuit's timing coincides with a tumultuous period for Skye, marked by the October 6, 2025 announcement of the trial results. Following this disclosure, Skye's stock price fell dramatically by nearly 60%, highlighting the impact of the trial's outcomes on investor confidence. The lawsuit claims that the misleading statements made by Skye about nimacimab's effectiveness inflated the company's perceived commercial and clinical prospects, ultimately leading to significant financial losses for investors when the truth was revealed. Investors are urged to act quickly, as they have until January 16, 2026, to apply for lead plaintiff status in the case.

Berger Montague, known for its expertise in complex civil litigation and class actions, is leading the charge against Skye. The firm has a strong track record, recovering over $50 billion for its clients throughout its 55-year history. Other law firms, including Schall Law Firm and Levi & Korsinsky, have also announced similar lawsuits against Skye, indicating a growing concern among investors about the company's transparency and corporate governance practices. As the situation develops, it will be crucial for Skye to address these allegations and restore investor confidence amid increasing scrutiny from the legal community.

In addition to the class action lawsuit, Skye Bioscience's challenges reflect broader trends in the biotechnology industry, where clinical trial results can dramatically influence investor sentiment and stock performance. The firm’s focus on addressing obesity and metabolic diseases places it in a competitive and rapidly evolving market, where effective communication with investors is essential.

As the legal proceedings unfold, affected shareholders are encouraged to reach out to legal representatives for guidance on their rights and options for recovery. This situation underscores the critical importance of maintaining transparency and accountability in corporate communications, particularly in the high-stakes biotechnology sector.